From: Anti-malarial drug: the emerging role of artemisinin and its derivatives in liver disease treatment
Derivatives | Molecular formulas | Chemical structures | Structural modifications | Physical properties | Formulations | Route of administration | Pharmacokinetics | Pharmacological activities | Ref |
---|---|---|---|---|---|---|---|---|---|
Artemisinin | C15H22O5 |
| - | Poorly soluble in water and oil; Melting point 156–157℃; Molecular weight 282.35 | Powder; Micronized powder; Tablet; Capsule; Suppository | Oral Intramuscular injection Rectal | Tmax 1–3 h Volume of distribution 1420–1560L Clearance 445–479L/h T1/2 2.27–2.29 h Tmax 3.4 h Tmax 5.6 h | Antimalaria; Antivirus; Antihelminth; Anticancer; Antiinflammation; | |
DHA | C15H24O5 |
| Modifying carbonyl groups into hydroxyl groups; The active metabolite of all artemisinins | Molecular weight 284.4 | Powder; Tablet; | Oral Intramuscular injection Rectal | Tmax 0.9–1.6 h – Tmax 4 h | Antimalaria; Anticancer; | |
ART | C19H28O8 |
| Hemisuccinate derivative of DHA | Water-soluble; Molecular weight 384.4 | Powder Suppository Tablet Injection | Oral Intramuscular injection Rectal Intravenous administration | Bioavailability 61%-88% Tmax 15–39 min Volume of distribution 14.8L/kg Clearance 20.6L/kg/hr T1/2 0.36–1.2 h Bioavailability 86.4–88% Tmax 7.2–12 min T1/2 25.2–48.2 h Clearance 2.4–3.48L/kg/hr Volume of distribution 1.09–3.98L/kg Bioavailability 54.9% Tmax 0.58–1.43 h T1/2 0.9–0.95 h Clearance 2–3L/kg/hr Volume of distribution 0.1–0.3L/kg | Antimalaria; Antiparasite; Antitumor; Antivirus; Antiinflammation; Antibacterial | |
ARM | C16H26O5 |
| Production methyl ether from DHA | Oil-soluble; Molecular weight 298.4 | Powder Injection Capsule | Oral Intramuscular injection Rectal | Tmax 1.7–6 h Tmax 1.3–8.7 h Tmax 3.1 h | Antimalaria | |
ARE | C17H28O5 |
| Production β-ethyl ether from DHA | Oil-soluble; Practically insoluble in water; Molecular weight 312.4 | Powder Injection | Oral Intramuscular injection Rectal | – Tmax 4.8–7 h – | Antimalaria |